<p>Cytek Biosciences（纳斯达克：CTKB - 获取免费报告）在周二发布给投资者的研究报告中，Piper Sandler 的股票分析师将其目标价格从 8.00 美元下调至 7.50 美元，Benzinga 报道。该券商目前对该股票的评级为 “超配”。Piper Sandler 的目标价格暗示该股票当前价格有 57.40% 的上涨潜力。</p>
<p>其他分析师最近也发布了关于该公司的研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Cytek Biosciences 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 4 日的报告中将 Cytek Biosciences 的股票评级从 “强力买入” 下调至 “持有”。两位股票研究分析师给予该股票买入评级，三位给予持有评级，另外两位给予卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价格为 5.50 美元。</p>
<p>获取 <strong>Cytek Biosciences</strong> 警报：</p>
<p><strong>阅读我们关于 Cytek Biosciences 的最新报告</strong></p>
<h2>Cytek Biosciences 价格表现</h2>
<p>周二，CTKB 的股票上涨 0.02 美元，达到 4.77 美元。该公司的股票交易量为 438,435 股，而其平均交易量为 978,443 股。该股票的 50 日简单移动平均为 3.95 美元，200 日简单移动平均为 3.62 美元。该股票的市值为 6.0928 亿美元，市盈率为-47.65，贝塔值为 1.33。Cytek Biosciences 的 12 个月低点为 2.37 美元，12 个月高点为 7.30 美元。</p>
<p>Cytek Biosciences（纳斯达克：CTKB - 获取免费报告）最后一次发布季度财报是在 11 月 28 日。该公司报告本季度每股收益为 0.04 美元。Cytek Biosciences 的净利润率为-6.51%，股本回报率为-3.35%。该业务本季度的收入为 4048 万美元。分析师预计 Cytek Biosciences 在本年度将发布-0.06 美元的每股收益。</p>
<h2>机构投资者对 Cytek Biosciences 的看法</h2>
<p>几家机构投资者和对冲基金最近修改了对 CTKB 的持股。Federated Hermes Inc.在第二季度将其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.现在拥有 7221 股该公司的股票，价值 25,000 美元，此前在上个季度增持了 4343 股。Brooklyn Investment Group 在第一季度将其在 Cytek Biosciences 的持股增加了 992,200.0%。Brooklyn Investment Group 现在拥有 9923 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 9922 股。Vanguard Personalized Indexing Management LLC 在第二季度购买了价值约 42,000 美元的 Cytek Biosciences 新股份。US Bancorp DE 在第一季度将其在 Cytek Biosciences 的持股增加了 9,698.2%。US Bancorp DE 现在拥有 10680 股该公司的股票，价值 43,000 美元，此前在上个季度增持了 10571 股。最后，Captrust Financial Advisors 在第二季度购买了价值约 43,000 美元的 Cytek Biosciences 新股份。机构投资者持有该公司 69.46% 的股票。</p>
<h2>Cytek Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cytek Biosciences, Inc.是一家细胞分析解决方案公司，提供细胞分析工具，以促进生物医学研究和临床应用的科学进步。它提供 aurora 和 northern lights 系统，这些是光谱流式细胞仪，通过利用多个激光的荧光特征来区分单个细胞上的荧光标签，从而提供细胞分析；以及 aurora 细胞分选系统，利用全光谱分析技术进一步拓宽细胞分析的潜在应用；aurora CS 系统；amnis imagestream 成像流式细胞仪；guava muse 细胞分析仪；guava easycyte 流式细胞仪；以及 orion 试剂鸡尾酒制备系统。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票：Cytek Biosciences</li>
<li>宠物是大生意：4 只值得加入您投资组合的大型宠物股票</li>
<li>巴里克的黄金季度：提升回购和股息</li>
<li>异常交易量的股票：如何实时发现异常交易量股票</li>
<li>Nebius 与 Meta 合作——人工智能增长可能将股票推向新高</li>
<li>如何计算期权利润</li>
<li>EVgo 的 37% 收入增长：忘掉汽车，买下加油站</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Cytek Biosciences 吗？</h2>
<p>在您考虑 Cytek Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cytek Biosciences 并不在名单上。</p>
<p>虽然 Cytek Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CTKB

<p>Piper Sandler 将 Cytek Biosciences (NASDAQ:CTKB) 的目标股价从 8.00 美元下调至 7.50 美元，同时维持 “增持” 评级。这意味着从当前价格 4.77 美元来看，潜在上涨幅度为 57.40%。其他分析师的评级则各有不同，平均共识为 “持有”，目标股价为 5.50 美元。Cytek 报告的季度收入为 4048 万美元，净利润率为负 6.51%。机构投资者持有该公司 69.46% 的股份</p>

<p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) had its price target cut by stock analysts at Piper Sandler from $8.00 to $7.50 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Piper Sandler's target price suggests a potential upside of 57.40% from the stock's current price.</p>
<div class="lb-trans"><p>Cytek Biosciences（纳斯达克：CTKB - 获取免费报告）在周二发布给投资者的研究报告中，Piper Sandler 的股票分析师将其目标价格从 8.00 美元下调至 7.50 美元，Benzinga 报道。该券商目前对该股票的评级为 “超配”。Piper Sandler 的目标价格暗示该股票当前价格有 57.40% 的上涨潜力。</p>
</div><p>Other analysts have also recently issued research reports about the company. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Cytek Biosciences in a research report on Wednesday, October 8th. Zacks Research lowered shares of Cytek Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $5.50.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该公司的研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Cytek Biosciences 股票的 “卖出（e+）” 评级。Zacks Research 在 11 月 4 日的报告中将 Cytek Biosciences 的股票评级从 “强力买入” 下调至 “持有”。两位股票研究分析师给予该股票买入评级，三位给予持有评级，另外两位给予卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价格为 5.50 美元。</p>
</div><p>Get <strong>Cytek Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cytek Biosciences</strong> 警报：</p>
</div><p><strong>Read Our Latest Report on Cytek Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Cytek Biosciences 的最新报告</strong></p>
</div><h2>Cytek Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Cytek Biosciences 价格表现</h2>
</div><p>Shares of CTKB traded up $0.02 on Tuesday, reaching $4.77. The company's stock had a trading volume of 438,435 shares, compared to its average volume of 978,443. The stock's 50 day simple moving average is $3.95 and its two-hundred day simple moving average is $3.62. The stock has a market capitalization of $609.28 million, a P/E ratio of -47.65 and a beta of 1.33. Cytek Biosciences has a 12-month low of $2.37 and a 12-month high of $7.30.</p>
<div class="lb-trans"><p>周二，CTKB 的股票上涨 0.02 美元，达到 4.77 美元。该公司的股票交易量为 438,435 股，而其平均交易量为 978,443 股。该股票的 50 日简单移动平均为 3.95 美元，200 日简单移动平均为 3.62 美元。该股票的市值为 6.0928 亿美元，市盈率为-47.65，贝塔值为 1.33。Cytek Biosciences 的 12 个月低点为 2.37 美元，12 个月高点为 7.30 美元。</p>
</div><p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its quarterly earnings results on Tuesday, November 28th. The company reported $0.04 earnings per share for the quarter. Cytek Biosciences had a negative net margin of 6.51% and a negative return on equity of 3.35%. The business had revenue of $40.48 million for the quarter. Analysts expect that Cytek Biosciences will post -0.06 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cytek Biosciences（纳斯达克：CTKB - 获取免费报告）最后一次发布季度财报是在 11 月 28 日。该公司报告本季度每股收益为 0.04 美元。Cytek Biosciences 的净利润率为-6.51%，股本回报率为-3.35%。该业务本季度的收入为 4048 万美元。分析师预计 Cytek Biosciences 在本年度将发布-0.06 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Cytek Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 Cytek Biosciences 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of CTKB. Federated Hermes Inc. boosted its position in shares of Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after acquiring an additional 4,343 shares during the last quarter. Brooklyn Investment Group lifted its stake in Cytek Biosciences by 992,200.0% in the 1st quarter. Brooklyn Investment Group now owns 9,923 shares of the company's stock worth $40,000 after purchasing an additional 9,922 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Cytek Biosciences during the second quarter valued at about $42,000. US Bancorp DE grew its position in shares of Cytek Biosciences by 9,698.2% during the first quarter. US Bancorp DE now owns 10,680 shares of the company's stock valued at $43,000 after purchasing an additional 10,571 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Cytek Biosciences in the second quarter worth about $43,000. Institutional investors own 69.46% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近修改了对 CTKB 的持股。Federated Hermes Inc.在第二季度将其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.现在拥有 7221 股该公司的股票，价值 25,000 美元，此前在上个季度增持了 4343 股。Brooklyn Investment Group 在第一季度将其在 Cytek Biosciences 的持股增加了 992,200.0%。Brooklyn Investment Group 现在拥有 9923 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 9922 股。Vanguard Personalized Indexing Management LLC 在第二季度购买了价值约 42,000 美元的 Cytek Biosciences 新股份。US Bancorp DE 在第一季度将其在 Cytek Biosciences 的持股增加了 9,698.2%。US Bancorp DE 现在拥有 10680 股该公司的股票，价值 43,000 美元，此前在上个季度增持了 10571 股。最后，Captrust Financial Advisors 在第二季度购买了价值约 43,000 美元的 Cytek Biosciences 新股份。机构投资者持有该公司 69.46% 的股票。</p>
</div><h2>Cytek Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Cytek Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc.是一家细胞分析解决方案公司，提供细胞分析工具，以促进生物医学研究和临床应用的科学进步。它提供 aurora 和 northern lights 系统，这些是光谱流式细胞仪，通过利用多个激光的荧光特征来区分单个细胞上的荧光标签，从而提供细胞分析；以及 aurora 细胞分选系统，利用全光谱分析技术进一步拓宽细胞分析的潜在应用；aurora CS 系统；amnis imagestream 成像流式细胞仪；guava muse 细胞分析仪；guava easycyte 流式细胞仪；以及 orion 试剂鸡尾酒制备系统。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cytek Biosciences</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>Barrick's Golden Quarter: Boosts Buyback and Dividend</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Nebius Partners With Meta—AI Growth Could Send Stock to New Highs</li>
<li>How to Calculate Options Profits</li>
<li>EVgo's 37% Revenue Growth: Forget the Car, Buy the Gas Station</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票：Cytek Biosciences</li>
<li>宠物是大生意：4 只值得加入您投资组合的大型宠物股票</li>
<li>巴里克的黄金季度：提升回购和股息</li>
<li>异常交易量的股票：如何实时发现异常交易量股票</li>
<li>Nebius 与 Meta 合作——人工智能增长可能将股票推向新高</li>
<li>如何计算期权利润</li>
<li>EVgo 的 37% 收入增长：忘掉汽车，买下加油站</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CTKB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytek Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Cytek Biosciences 吗？</h2>
</div><p>Before you consider Cytek Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Cytek Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cytek Biosciences 并不在名单上。</p>
</div><p>While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cytek Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cytek Biosciences（纳斯达克代码：CTKB）的目标价在派杰被下调至 7.50 美元